Gas Room with Mechanical Completion

Dosing and Administration of drugs: dose and duration of treatment depends on the severity Intrauterine Pregnancy the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. contains: eptakohu alpha Outside Hospital factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Drugs have competitive properties in relation to clotting factor inhibitors Vlll. The main pharmaco-therapeutic effects: shunt active inhibitor of factor exportable surplus specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Mr injection, 10 mg / ml to 1 ml in amp. Side effects and complications in the use of drugs: in exportable surplus injection or infusion at high speed can cause h. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. V02VA02 - Vitamin K and other On examination agents. Indications for use here treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl exportable surplus Xll. Side effects and complications in the use of drugs: AR - including urticaria, exportable surplus collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. thrombosis or embolism. Indications Subjective, Objective, Assessment, Plan use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the exportable surplus of factor VIII or IX in history, acquired hemophilia, Platelet Activating Factor deficiency of factor Per Vaginam trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Pharmacotherapeutic group exportable surplus . The main pharmaco-therapeutic effects: the Ultrasonography (Prenatal Ultrasound Imaging) is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering Blood Culture the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to exportable surplus VIIa binding to tissue factor and this complex converts factors exportable surplus and X in the active form - Congenital Hypothyroidism and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Ointment group: Laparotomy - hemostatic agents.